The Diagnostic Imaging mammography modality focus page provides information, videos, podcasts, and the latest news about industry product developments, trial results, screening guidelines, and protocol guidance that touch on the use of mammography, including 2D digital mammography, digital breast tomosynthesis, and breast ultrasound.
September 17th 2025
Digital breast tomosynthesis (DBT) and synthesized mammography offered a true-positive recall rate of 8.4 per 1,000 women screened vs. 6.2 for digital mammography alone, according to a study involving over 99,000 women.
Mammography Study: AI Improves Breast Cancer Detection and Reduces Reading Time with DBT
April 3rd 2024An emerging artificial intelligence (AI) model demonstrated more than 12 percent higher specificity and reduced image reading time by nearly six seconds in comparison to unassisted radiologist interpretation of digital breast tomosynthesis (DBT) images.
Five Insights on Artifacts and Limitations with Contrast-Enhanced Mammography
February 29th 2024Noting that technique issues, patient positioning miscues and atypical features can all contribute to faulty interpretation with contrast-enhanced mammography (CEM), researchers at the European Congress of Radiology shared their insights on navigating artifacts and limitations with CEM.
Study Shows Benefits of Annual Mammography Exams from 40 to 79 Years of Age
February 21st 2024In comparison to biennial mammography screening between the ages of 50 to 74, researchers found that annual screening between 40 and 79 years of age resulted in a greater than 16 percent higher reduction in breast cancer mortality.
Moving Beyond Mammography for Screening and Staging of Invasive Lobular Carcinoma
February 16th 2024For women with dense breasts, only 25 percent of breast radiologists are confident in the use of mammography for diagnosing invasive lobular carcinoma, according to newly published survey results from the Society of Breast Imaging.
Assessing the Potential of Positron Emission Mammography: An Interview with Vivianne Freitas, MD
February 12th 2024In a recent interview, Vivianne Freitas, M.D., discussed new research findings on positron emission mammography (PEM), pertinent benefits of the technology and its potential as a viable alternative in the future to conventional imaging techniques for breast cancer screening.
Can Positron Emission Mammography Have an Impact in Diagnosing Invasive Breast Cancer?
February 9th 2024Findings from a new pilot study showed that low-dose positron emission mammography (PEM) detected 96 percent of malignant index lesions and had a 46 percent lower false-positive rate in comparison to breast MRI.
Key Takeaways from Multiple Radiology Societies on AI Assessment and Integration
January 22nd 2024In a recently issued statement from multiple radiology societies including the RSNA and ACR, researchers offer practical advice for evaluating artificial intelligence (AI) tools, implementing AI into current workflows and monitoring of the technology to help ensure optimal benefit and effectiveness.
Study: Abbreviated MRI and DBT Offer Comparable Breast Cancer Detection in Dense Breasts
January 17th 2024For women with dense breasts, abbreviated breast MRI and digital breast tomosynthesis (DBT) both offered greater than 98 percent sensitivity rates and greater than 94 percent negative predictive values (NPVs) for breast cancer detection, according to newly published research.
Can a Genetic Model Help Reduce Overuse of Mammography in Women at Low Risk for Breast Cancer?
January 2nd 2024In a study assessing the use of a genetic risk stratification model to estimate breast cancer risk in over 25,000 women, researchers found that 0.69 percent of women at low genetic risk were diagnosed with breast cancer by the age of 45 and 1.41 percent of this group were diagnosed by the age of 58.
Mammography Surveillance: Can Screening DBT Have an Impact After Breast Cancer Treatment?
December 22nd 2023In a study of over 30,000 screening digital breast tomosynthesis (DBT) exams for over 8,000 women, researchers found a specificity rate of 95.1 percent, a false negative rate of 2.1 (per 1,000 exams) and an abnormal interpretation rate (AIR) of 5.7 percent.
Can ChatGPT and Bard Bolster Decision-Making for Cancer Screening in Radiology?
December 21st 2023In a study examining the potential of the large language models ChatGPT-4 and Bard to follow ACR Appropriateness Criteria for breast cancer, lung cancer, ovarian cancer and colorectal cancer screening, researchers noted “impressive accuracy in making radiologic clinical decisions.”